A Phase 1 interventional study of Abemaciclib and Pemetrexed in Carcinoma, Non-small Cell Lung, sponsored by Eli Lilly and Company. Completed at 11 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-09-11.
Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung — 2 open to participants now, 9 under way, 2 of them phase 3. Ramucirumab · Carcinoma, Non-Small-Cell Lung.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, this one is the 10th largest by enrollment, is one of 2 that started in 2014, is one of 4 in phase 1, and was the 5th registered.
7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.
Browse Carcinoma, Non-Small-Cell Lung studies →2 of the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung are open now, in 12 countries. Recruiting first, the newest first:
AstraZeneca · Sites in United States, Belgium, Brazil and 17 more countries
Ages 18+
SWOG Cancer Research Network · Sites in United States
Ages 18 min+
By country, each count listing its studies:
Ramucirumab: first FDA approval 2014 (CYRAMZA), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
24 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 17 · Phase 3 3
First in 2009; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 142 is above the median of 62 across 6,024 interventional studies indexed under Carcinoma, Non-Small-Cell Lung.
Median enrollment 74 across the 24 interventional studies. Of the 14 that completed or were terminated, 13 (93%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 24 have an industry lead sponsor. The 10 most frequent:
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company: 6 open now, 20 under way, 6 of them phase 3. Of 121 finished, 81 (67%) have results posted.
Among the 147 studies in Carcinoma, Non-Small-Cell Lung by Eli Lilly and Company, this one is the 58th largest by enrollment of the 139 interventional ones that give a count, is one of 3 that started in 2014, is one of 28 in phase 1, and was the 103rd registered.
Eli Lilly and Company’s Carcinoma, Non-Small-Cell Lung studies by the year they started, since 2000.
2 of the studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03527108Fox Chase Cancer CenterNivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic NSCLC | 2026-12 |
| NCT03909334Xiuning LeStudy of Osimertinib With and Without Ramucirumab in Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) | 2026-12 |
Add all 2 to your calendar (.ics) → With an account.
Among the 24 studies testing ramucirumab in Carcinoma, Non-Small-Cell Lung, from their registry updates:
Among Eli Lilly and Company’s 147 in Carcinoma, Non-Small-Cell Lung:
This tab as a report to print or save as PDF → With an account.
The main purpose of this study is to evaluate the safety and tolerability of abemaciclib in combination with another anti-cancer drug in participants with NSCLC that is advanced or has spread to other parts of the body (stage IV). The study will also investigate how the body processes the combination treatment and how the study drug affects the body. The study will also collect disease-related symptoms and participant-reported pain related to NSCLC.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Have adequate organ function including:
Exclusion Criteria:
Additional Exclusion Criteria For Part C
History or evidence of cardiovascular risk including any of the following:
Additional Exclusion Criteria For Part D
Additional Exclusion Criteria for Part E
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
RECIST
The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.
“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
150 milligram (mg) or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 500 milligrams/square meter (mg/m\^2) pemetrexed given intravenously (IV) over approximately 10 minutes on Day 1 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib · Drug: Pemetrexed
150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 1250 milligram/square meter (mg/m\^2) gemcitabine given intravenously over approximately 30 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib · Drug: Gemcitabine
150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Day 1 or 8 to 10 milligram/kilogram (mg/kg) ramucirumab given intravenously over approximately 60 minutes on Days 1 and 8 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib · Drug: Ramucirumab
100 mg or 150 mg or 200 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 100, 150, or 200 mg LY3023414 given orally every 12 hours on Days 1 through 21 of a 21-day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib · Drug: LY3023414
100 mg or 150 mg abemaciclib given orally every 12 hours on Days 1 through 21 of a 21-day cycle in combination with 200 mg pembrolizumab given intravenously over approximately 30 minutes on day 1 of a 21 day cycle. Participants may continue to receive treatment until discontinuation criteria are met.
Drug: Abemaciclib · Drug: Pembrolizumab
Administered orally
Also known as: LY2835219
Administered IV
Also known as: Alimta
Administered IV
Also known as: Gemzar
Administered IV
Also known as: Cyramza
Administered orally
Administered IV
Also known as: Keytruda
Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E
A DLT defined as adverse event(AE) occurring between Day 1 and Day 21 of Cycle 1 that was considered at least possibly related to either abemaciclib or the combination therapy and fulfilled a criteria selected (using the National Cancer Institute Common Terminology Criteria for Adverse Events,version 4.0 \[NCI-CTCAE v 4.0\] \[NCI 2009\]):Grade(Gr)≥3 nonhematological toxicity,Gr4 thrombocytopenia lasting at least 5 days and/or complicated with bleeding,Gr≥3 febrile neutropenia(ntr) and for Part D participants (pts): Gr3 hyperglycemia (fasting) of \<5 days, Gr3 hypertriglyceridemia or hyperlipidemia without optimal treatment.A DLT-equivalent defined as AE that would have met the criteria for DLT if it had occurred during Cycle 1 for pts enrolled in dose-escalation phase,but that occurs between 1)Day 1 and Day 21 of Cycle 2 and beyond for a participant enrolled in dose-escalation phase 2) at any time for a participant in dose-expansion phase.
Time frame: Baseline through study completion (Up To 15 Months)
Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) in Part A, B, C, D and E
ORR is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of not-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
Time frame: Baseline through study completion (Up To 15 Months)
Progression Free Survival Time in Part A, B, C, D and E
Progression free survival (PFS) defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. PFS time was summarized using Kaplan-Meier estimates.
Time frame: Date of first dose until first documented progression or death (Up To 15 Months)
Change From Baseline in MD Anderson Symptom Inventory Scale-Lung Cancer (MDASI-LC) in Part A, B, C, D and E
The MDASI-LC is a self-reported lung cancer instrument included 22 items covered by one of the following dimensions: Mean core symptom severity (Core items 1-13: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sad, vomiting, numbness/tingling), Lung cancer symptoms (3 items: coughing, constipation, sore throat), Mean symptom severity (13 core items plus 3 lung items) and Interference with mood or functional status (6 items: general activity, mood, work, relations with other people, walking, enjoyment of life). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.
Time frame: Baseline, through study completion (Up To 15 Months)
Pharmacokinetics (PK): Maximum Concentration (Cmax) of Abemaciclib on Day 1 and at Steady State (Cycle 2 Day 1) in Part A , B, C, D and E
Cmax of Abemaciclib on day 1 and at steady State (Cycle 2 Day 1) Part A , B, C, D and E was evaluated.
Time frame: Cycle 1 Day 1 (C1D1) pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; Cycle 2 Day 1 (C2D1) pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
Pharmacokinetics: Maximum Concentration (Cmax) of Pemetrexed at Steady State in Part A
Cmax of pemetrexed at steady state in Part A was evaluated.
Time frame: C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
PK: Dose-normalized Maximum Concentration (Cmax) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B
Cmax of active gemcitabine metabolite (dFdU) on day 1 and at steady state (Cycle 2 Day 1) dose-normalized to 1250 mg/m\^2 in Part B was evaluated.
Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
PK: Maximum Concentration (Cmax) of Ramucirumab at 1 Hour Post-End-of-Infusion in Part C
Cmax of ramucirumab at 1 hour post-end-of-Infusion in Part C was evaluated.
Time frame: C1D1 and C2D1: 1 hour post-end-of-infusion
PK: Maximum Concentration (Cmax) of LY3023414 in Part D
Cmax of LY3023414 in Part D was evaluated.
Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
PK: Area Under the Concentration Curve (AUC) of Abemaciclib in Part A, B, C, D and E
Area under the concentration time curve from zero to 8 hours AUC(0-8h) of abemaciclib in Part A, B, C, D and E was evaluated.
Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
PK: Area Under the Concentration Curve (AUC) of Pemetrexed at Steady State in Part A
Area under the plasma concentration versus time curve from time zero to infinity (AUC\[0-∞\]) of Pemetrexed in Part A was evaluated.
Time frame: C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
PK: Area Under the Concentration Curve (AUC) of Active Gemcitabine Metabolite: 2',2'-Difluorodeoxyuridine (dFdU) on Day 1 and at Steady State (Cycle 2 Day 1) in Part B
Area under the plasma concentration time curve from time zero to 12 hours (AUC\[0-12h\]) of active gemcitabine metabolite (dFdU) in Part B was evaluated
Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
PK: Area Under the Concentration Curve (AUC) of LY3023414 in Part D
Area under the plasma concentration versus time curve from time zero to infinity (AUC) of LY3023414 in Part D was evaluated. For Day 1, AUC is defined as AUC from time zero to infinity (AUC\[0-∞\]), for steady state, AUC is defined as AUC from time zero to the end of the dosing interval, tau (AUC\[0-tau \])
Time frame: C1D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose; C2D1 pre-dose and 1, 2, 4, 6, 8, 10 h post-dose
| Milestone | Part A: 150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C: 150 mg Abemaciclib + 10mg/kg Ramucirumab Day 1 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Started | 8 | 15 | 3 | 21 | 4 | 19 | 12 | 4 | 3 | 9 | 10 | 6 | 8 | 3 | 17 |
| Received at least one dose of study drug | 8 | 15 | 3 | 21 | 4 | 19 | 12 | 4 | 3 | 9 | 10 | 6 | 8 | 3 | 17 |
| Completed | 5 | 13 | 3 | 9 | 2 | 13 | 11 | 3 | 3 | 6 | 8 | 4 | 5 | 3 | 12 |
| Not completed | 3 | 2 | 0 | 12 | 2 | 6 | 1 | 1 | 0 | 3 | 2 | 2 | 3 | 0 | 5 |
| Withdrew: Death | 2 | 1 | 0 | 5 | 1 | 2 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| Withdrew: Adverse event | 1 | 1 | 0 | 1 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Progressive disease | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 | 0 | 1 | 0 | 0 | 0 | 2 | 1 | 1 | 1 | 0 | 2 |
| Withdrew: Physician decision | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 0 | 1 |
| Withdrew: Lost to follow-up | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
A DLT defined as adverse event(AE) occurring between Day 1 and Day 21 of Cycle 1 that was considered at least possibly related to either abemaciclib or the combination therapy and fulfilled a criteria selected (using the National Cancer Institute Common Terminology Criteria for Adverse Events,version 4.0 \[NCI-CTCAE v 4.0\] \[NCI 2009\]):Grade(Gr)≥3 nonhematological toxicity,Gr4 thrombocytopenia lasting at least 5 days and/or complicated with bleeding,Gr≥3 febrile neutropenia(ntr) and for Part D participants (pts): Gr3 hyperglycemia (fasting) of \<5 days, Gr3 hypertriglyceridemia or hyperlipidemia without optimal treatment.A DLT-equivalent defined as AE that would have met the criteria for DLT if it had occurred during Cycle 1 for pts enrolled in dose-escalation phase,but that occurs between 1)Day 1 and Day 21 of Cycle 2 and beyond for a participant enrolled in dose-escalation phase 2) at any time for a participant in dose-expansion phase.
| Participants | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10 mg/kg Ramucirumab Day 1 | Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day 1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants With Dose-Limiting Toxicities (DLT) or DLT-equivalent in Part A, B, C, D and E | 1 | 4 | 0 | 5 | 1 | 4 | 1 | 3 | 1 | 1 | 1 | 1 | 2 | 0 | 0 |
ORR is the best response of CR or PR as classified by the investigators according to the Response Evaluation Criteria In Solid Tumors (RECIST v1.1). CR is a disappearance of all target and non-target lesions and normalization of tumor marker level. PR is an at least 30% decrease in the sum of the diameters of target lesions (taking as reference the baseline sum diameter) without progression of not-target lesions or appearance of new lesions. Overall response rate is calculated as a total number of participants with CR or PR divided by the total number of participants with at least 1 measurable lesion, multiplied by 100.
| Participants | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day 1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Number of Participants Achieving Complete Response (CR) or Partial Response (PR) (Overall Response Rate [ORR]) in Part A, B, C, D and E | 0 | 1 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 2 |
Progression free survival (PFS) defined as the time from the date of randomization to the first evidence of disease progression as defined by response evaluation criteria in solid tumors (RECIST) v1.1 or death from any cause. Progressive Disease (PD) was at least a 20% increase in the sum of the diameters of target lesions, with reference being the smallest sum on study and an absolute increase of at least 5 mm, or unequivocal progression of non-target lesions, or 1 or more new lesions. If a participant does not have a complete baseline disease assessment, then the PFS time was censored at the date of randomization, regardless of whether or not objectively determined disease progression or death has been observed for the participant. If a participant was not known to have died or have objective progression as of the data inclusion cutoff date for the analysis, the PFS time was censored at the last adequate tumor assessment date. PFS time was summarized using Kaplan-Meier estimates.
| Months | Part A:Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:Abemaciclib+ 8/10mg/kg Ramucirumab Day1/8 | Part D: Abemaciclib + 100 mg/150 mg/ 200 mg LY3023414 | Part E: 100 mg/150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|
| Progression Free Survival Time in Part A, B, C, D and E | 5.55 (1.81 to 22.47) | 1.58 (1.18 to 2.46) | 4.83 (1.61 to 7.16) | 1.87 (1.41 to 5.32) | 4.11 (3.02 to NA) |
The MDASI-LC is a self-reported lung cancer instrument included 22 items covered by one of the following dimensions: Mean core symptom severity (Core items 1-13: pain, fatigue, nausea, disturbed sleep, distress, shortness of breath, remembering things, lack of appetite, drowsy, dry mouth, sad, vomiting, numbness/tingling), Lung cancer symptoms (3 items: coughing, constipation, sore throat), Mean symptom severity (13 core items plus 3 lung items) and Interference with mood or functional status (6 items: general activity, mood, work, relations with other people, walking, enjoyment of life). The mean of all symptom subscale items was calculated where 0 equals "not present" and 10 equals "as bad as you can imagine." A change from baseline with negative values indicate improvement, positive values indicate worsening.
| units on a scale | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean core symptom severity | -0.16 (-1.46 to 0.31) | 0.89 (-0.96 to 2.24) | -0.54 (-0.54 to -0.54) | -0.08 (-1.54 to 1.08) | -0.35 (-2.47 to 1.77) | 0.61 (-1.04 to 2.70) | -0.64 (-1.54 to 1.23) | -1.39 (-2.31 to -0.46) | 0.61 (-1.85 to 2.15) | 1.89 (1.00 to 3.85) | 1.60 (-1.15 to 2.77) | -0.80 (-2.93 to 0.38) | 0.28 (-1.62 to 2.18) | 0.91 (0.19 to 1.93) | 0.88 (0.47 to 2.08) |
| Mean symptom severity | -0.05 (-1.43 to 0.68) | 0.83 (-0.86 to 1.82) | -0.44 (-0.44 to -0.44) | -0.03 (-1.44 to 1.19) | -0.41 (-2.31 to 1.50) | 0.72 (-0.88 to 2.41) | -0.61 (-1.25 to 1.06) | -1.01 (-2.13 to 0.12) | 0.64 (-1.63 to 1.94) | 1.86 (1.50 to 3.62) | 1.60 (-0.94 to 2.88) | -0.73 (-2.82 to 0.37) | 0.19 (-1.35 to 1.73) | 0.99 (0.59 to 1.69) | 0.75 (0.56 to 1.94) |
| Mean lung cancer symptom | 1.22 (-1.00 to 3.33) | 0.71 (-1.00 to 1.00) | 1.67 (1.67 to 1.67) | 0.19 (-1.00 to 1.00) | -0.67 (-1.67 to 0.33) | 1.13 (-1.00 to 2.00) | -0.78 (-3.00 to 0.67) | 3.01 (2.67 to 3.34) | 0.78 (-0.67 to 2.00) | 1.40 (-0.34 to 2.66) | 2.19 (0.67 to 3.33) | -0.44 (-2.33 to 1.34) | 0.67 (-1.00 to 2.34) | 1.67 (0.67 to 2.33) | 0.23 (-1.00 to 1.67) |
| Mean interference severity | 2.32 (1.50 to 4.20) | 0.49 (-3.00 to 3.59) | 0.00 (0.00 to 0.00) | 0.95 (-0.51 to 4.76) | -1.33 (-3.83 to 1.17) | 0.15 (-3.00 to 3.16) | -1.00 (-5.16 to 1.33) | -3.08 (-4.50 to -1.66) | 0.72 (-1.17 to 3.50) | 1.47 (0.17 to 1.67) | 1.81 (-0.83 to 5.17) | -0.22 (-3.17 to 2.17) | -0.38 (-4.25 to 3.50) | 1.44 (0.33 to 2.83) | 1.00 (-1.67 to 2.84) |
Cmax of Abemaciclib on day 1 and at steady State (Cycle 2 Day 1) Part A , B, C, D and E was evaluated.
| nanograms per milliliter (ng/mL) | Part A:150 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C: 150 mg Abemaciclib + 8 mg/kg or 10 mg/kg Ramucirumab | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day 1 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 or 150 or 200 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 114 ± 67.4 | 212 ± 79.8 | 80.6 ± 14.7 | 201 ± 71.7 | 140 ± 95.7 | 195 ± 85.8 | 86.2 ± 91.1 | 159 ± 74.1 | 225 ± 103 | 125 ± 57.2 | 114 ± 68.8 |
| Steady State | NA ± NA | 509 ± 40.5 | NA ± NA | 417 ± 77.7 | 322 ± 112 | 228 ± 152 | 227 ± 85.1 | 305 ± 55.8 | — | 270 ± 47.7 | 240 ± 87.5 |
Cmax of pemetrexed at steady state in Part A was evaluated.
| microgram per milliliter (μg/mL) | Part A:150 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed |
|---|---|---|
| Pharmacokinetics: Maximum Concentration (Cmax) of Pemetrexed at Steady State in Part A | 98.1 ± 29 | 93.5 ± 30 |
Cmax of active gemcitabine metabolite (dFdU) on day 1 and at steady state (Cycle 2 Day 1) dose-normalized to 1250 mg/m\^2 in Part B was evaluated.
| nanogram per milliliter (ng/mL) | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg or MTD Abemaciclib + 1250 mg/m^2 Gemcitabine |
|---|---|---|---|
| Day 1 | 35600 ± 14 | 49600 ± 12 | 41900 ± 21 |
| Steady State | NA ± NA | 38700 ± 18 | 35800 ± 17 |
Cmax of ramucirumab at 1 hour post-end-of-Infusion in Part C was evaluated.
| microgram per milliliter (μg/mL) | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day 1 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 |
|---|---|---|---|---|
| C1D1 | 174 ± 19.6 | 226 ± 10.0 | 193 ± 27.0 | 221 ± 30.6 |
| C2D1 | 221 ± 15.0 | NA ± NA | NA ± NA | 226 ± 32.3 |
Cmax of LY3023414 in Part D was evaluated.
| nanograms per milliliter (ng/mL) | Part D: 100 or 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 or 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 |
|---|---|---|---|
| Day 1 | 298 ± 104 | 454 ± 81 | 578 ± 119 |
| Steady State | 438 ± 63 | 491 ± 52 | NA ± NA |
Area under the concentration time curve from zero to 8 hours AUC(0-8h) of abemaciclib in Part A, B, C, D and E was evaluated.
| nanogram*hour/mL (ng*h/mL) | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C: 150 mg Abemaciclib + 8 mg/kg or 10 mg/kg Ramucirumab | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 or 150 or 200 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Day 1 | 533 ± 69.6 | 979 ± 77.5 | 393 ± 31.0 | 886 ± 53.4 | 797 ± 69.0 | 1030 ± 127 | 394 ± 71.7 | 719 ± 77.3 | 967 ± 139 | NA ± NA | 518 ± 21.6 |
| Steady State | NA ± NA | 3710 ± 41.1 | NA ± NA | 2690 ± 53.4 | 1720 ± 119 | 1840 ± 115 | NA ± NA | 1550 ± 83.7 | — | — | 1400 ± 184 |
Area under the plasma concentration versus time curve from time zero to infinity (AUC\[0-∞\]) of Pemetrexed in Part A was evaluated.
| microgram*hour per milliliter (μg*hr/mL) | Part A:150 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed |
|---|---|---|
| PK: Area Under the Concentration Curve (AUC) of Pemetrexed at Steady State in Part A | 201 ± 30 | 198 ± 32 |
Area under the plasma concentration time curve from time zero to 12 hours (AUC\[0-12h\]) of active gemcitabine metabolite (dFdU) in Part B was evaluated
| nanogram*hour/mL (ng*h/mL) | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | 200 mg or MTD Abemaciclib + 1250 mg/m^2 Gemcitabine |
|---|---|---|---|
| Day 1 | 175000 ± 16 | 246000 ± 29 | 198000 ± 26 |
| Steady State | NA ± NA | 208000 ± 20 | 210000 ± 23 |
Area under the plasma concentration versus time curve from time zero to infinity (AUC) of LY3023414 in Part D was evaluated. For Day 1, AUC is defined as AUC from time zero to infinity (AUC\[0-∞\]), for steady state, AUC is defined as AUC from time zero to the end of the dosing interval, tau (AUC\[0-tau \])
| nanogram*hour/mL (ng*h/mL) | Part D: 100 or 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 or 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 |
|---|---|---|---|
| Day 1 | 1005 ± 63 | 1751 ± 56 | 3809 ± 95 |
| Steady State | 1303 ± 64 | 1293 ± 49 | NA ± NA |
Collected over Up to 4 years and 1 Month. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part A:150 mg Abemaciclib + 500 mg/m^2 Pemetrexed | 2/8 (25%) | 4/8 (50%) | 8/8 (100%) |
| Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | 1/15 (6.7%) | 8/15 (53.3%) | 15/15 (100%) |
| Part B:150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | 1/3 (33.3%) | 1/3 (33.3%) | 3/3 (100%) |
| Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | 6/21 (28.6%) | 10/21 (47.6%) | 21/21 (100%) |
| Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day1 | 2/4 (50%) | 3/4 (75%) | 4/4 (100%) |
| Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day1 | 4/19 (21.1%) | 12/19 (63.2%) | 19/19 (100%) |
| Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | 1/12 (8.3%) | 3/12 (25%) | 12/12 (100%) |
| Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | 1/4 (25%) | 3/4 (75%) | 4/4 (100%) |
| Part D: 100 mg Abemaciclib + 100 mg LY3023414 | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| Part D: 150 mg Abemaciclib + 100 mg LY3023414 | 1/9 (11.1%) | 2/9 (22.2%) | 8/9 (88.9%) |
| Part D: 150 mg Abemaciclib + 150 mg LY3023414 | 0/10 (0%) | 3/10 (30%) | 10/10 (100%) |
| Part D: 200 mg Abemaciclib + 150 mg LY3023414 | 1/6 (16.7%) | 0/6 (0%) | 5/6 (83.3%) |
| Part D: 150 mg Abemaciclib + 200 mg LY3023414 | 1/8 (12.5%) | 4/8 (50%) | 8/8 (100%) |
| Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | 0/3 (0%) | 0/3 (0%) | 3/3 (100%) |
| Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab | 2/17 (11.8%) | 9/17 (52.9%) | 16/17 (94.1%) |
| Event | Part A:150 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B:150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Coronary artery diseaseCardiac disorders | 0/8 | 0/15 | 0/3 | 0/21 | 0/4 | 0/19 | 0/12 | 0/4 | 1/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| PancreatitisGastrointestinal disorders | 0/8 | 0/15 | 0/3 | 0/21 | 0/4 | 0/19 | 0/12 | 0/4 | 1/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| PneumoniaInfections and infestations | 0/8 | 1/15 | 0/3 | 3/21 | 1/4 | 1/19 | 0/12 | 1/4 | 1/3 | 1/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Renal failureRenal and urinary disorders | 0/8 | 1/15 | 0/3 | 0/21 | 0/4 | 1/19 | 0/12 | 0/4 | 1/3 | 0/9 | 1/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| DyspnoeaRespiratory, thoracic and mediastinal disorders | 0/8 | 1/15 | 1/3 | 1/21 | 0/4 | 0/19 | 1/12 | 0/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Cardiac arrestCardiac disorders | 0/8 | 0/15 | 0/3 | 0/21 | 1/4 | 0/19 | 0/12 | 0/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Myocardial infarctionCardiac disorders | 0/8 | 0/15 | 0/3 | 0/21 | 0/4 | 0/19 | 0/12 | 1/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Septic shockInfections and infestations | 0/8 | 0/15 | 0/3 | 0/21 | 0/4 | 1/19 | 0/12 | 1/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Myocardial strainInvestigations | 0/8 | 0/15 | 0/3 | 0/21 | 1/4 | 0/19 | 0/12 | 0/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Subclavian artery thrombosisVascular disorders | 0/8 | 0/15 | 0/3 | 0/21 | 0/4 | 0/19 | 0/12 | 1/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Event | Part A:150 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B:150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10 mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NauseaGastrointestinal disorders | 5/8 | 6/15 | 3/3 | 13/21 | 1/4 | 12/19 | 6/12 | 2/4 | 2/3 | 5/9 | 6/10 | 3/6 | 4/8 | 0/3 | 7/17 |
| FatigueGeneral disorders | 5/8 | 12/15 | 2/3 | 17/21 | 2/4 | 12/19 | 5/12 | 0/4 | 2/3 | 4/9 | 4/10 | 2/6 | 2/8 | 3/3 | 12/17 |
| DiarrhoeaGastrointestinal disorders | 4/8 | 14/15 | 1/3 | 13/21 | 2/4 | 14/19 | 10/12 | 2/4 | 2/3 | 6/9 | 9/10 | 1/6 | 6/8 | 1/3 | 10/17 |
| AnaemiaBlood and lymphatic system disorders | 6/8 | 12/15 | 1/3 | 10/21 | 0/4 | 5/19 | 2/12 | 0/4 | 2/3 | 3/9 | 2/10 | 0/6 | 3/8 | 2/3 | 6/17 |
| VomitingGastrointestinal disorders | 3/8 | 4/15 | 0/3 | 8/21 | 1/4 | 11/19 | 3/12 | 1/4 | 2/3 | 4/9 | 7/10 | 2/6 | 6/8 | 0/3 | 4/17 |
| AstheniaGeneral disorders | 0/8 | 1/15 | 0/3 | 2/21 | 0/4 | 0/19 | 4/12 | 3/4 | 0/3 | 0/9 | 1/10 | 1/6 | 2/8 | 0/3 | 3/17 |
| Decreased appetiteMetabolism and nutrition disorders | 4/8 | 9/15 | 0/3 | 9/21 | 1/4 | 6/19 | 6/12 | 3/4 | 1/3 | 2/9 | 3/10 | 2/6 | 5/8 | 1/3 | 9/17 |
| Lung infectionInfections and infestations | 0/8 | 0/15 | 2/3 | 1/21 | 0/4 | 0/19 | 0/12 | 0/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
| Upper respiratory tract infectionInfections and infestations | 0/8 | 0/15 | 1/3 | 0/21 | 0/4 | 1/19 | 0/12 | 0/4 | 0/3 | 0/9 | 0/10 | 0/6 | 0/8 | 2/3 | 5/17 |
| Neutrophil count decreasedInvestigations | 5/8 | 4/15 | 2/3 | 9/21 | 0/4 | 3/19 | 1/12 | 1/4 | 2/3 | 0/9 | 0/10 | 0/6 | 0/8 | 0/3 | 0/17 |
All randomized participants who received at least one dose of study drug in Part A, B, C, D and E.
| Age, Continuous(years) | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mean | 63.88 ± 7.61 | 62.53 ± 11.19 | 55.00 ± 8.66 | 63.14 ± 10.07 | 61.25 ± 14.24 | 66.11 ± 9.31 | 63.75 ± 6.77 | 67.75 ± 4.92 | 67.00 ± 9.54 | 57.56 ± 8.26 | 64.00 ± 8.41 | 65.50 ± 7.48 | 60.38 ± 10.20 | 67.33 ± 3.51 | 59.76 ± 9.94 | 62.89 ± 9.30 |
| Sex: Female, Male(Participants) | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Female | 4 | 5 | 0 | 11 | 2 | 10 | 4 | 0 | 1 | 5 | 3 | 2 | 5 | 1 | 10 | 63 |
| Male | 4 | 10 | 3 | 10 | 2 | 9 | 8 | 4 | 2 | 4 | 7 | 4 | 3 | 2 | 7 | 79 |
| Ethnicity (NIH/OMB)(Participants) | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 1 | 1 | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 | 7 |
| Not Hispanic or Latino | 8 | 13 | 2 | 20 | 4 | 17 | 11 | 4 | 3 | 9 | 10 | 5 | 7 | 3 | 17 | 133 |
| Unknown or Not Reported | 0 | 1 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Race (NIH/OMB)(Participants) | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 |
| Asian | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 1 | 7 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 1 | 2 | 0 | 0 | 0 | 0 | 0 | 5 |
| White | 8 | 13 | 3 | 16 | 4 | 18 | 12 | 4 | 2 | 7 | 10 | 5 | 7 | 3 | 16 | 128 |
| More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | Part A:150 Milligram(mg) Abemaciclib + 500 mg/m^2 Pemetrexed | Part A: 200 mg Abemaciclib + 500 mg/m^2 Pemetrexed | Part B: 150 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part B: 200 mg Abemaciclib + 1250 mg/m^2 Gemcitabine | Part C:150 mg Abemaciclib+10mg/kg Ramucirumab Day1 | Part C: 200 mg Abemaciclib + 10mg/kg Ramucirumab Day1 | Part C: 150 mg Abemaciclib + 8 mg/kg Ramucirumab Days 1 and 8 | Part C: 150 mg Abemaciclib + 10 mg/kg Ramucirumab Days 1 and 8 | Part D: 100 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 100 mg LY3023414 | Part D: 150 mg Abemaciclib + 150 mg LY3023414 | Part D: 200 mg Abemaciclib + 150 mg LY3023414 | Part D: 150 mg Abemaciclib + 200 mg LY3023414 | Part E: 100 mg Abemaciclib + 200 mg Pembrolizumab | Part E: 150 mg Abemaciclib + 200 mg Pembrolizumab | Total |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | 6 | 8 | 2 | 16 | 4 | 15 | 6 | 1 | 3 | 9 | 10 | 6 | 8 | 0 | 3 | 97 |
| Spain | 2 | 7 | 1 | 5 | 0 | 4 | 6 | 3 | 0 | 0 | 0 | 0 | 0 | 3 | 14 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Mar 2014 to primary completion in May 2018, 49 months.
Results were first posted in Sep 2020, 2 years 4 months after primary completion.
Of 474 industry-sponsored phase 1 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 49 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 66. This study's 49 months is close to that.
Counting every sponsor, half of 700 studies reached it within 50 months; a quarter within 31 and three quarters within 70.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Abemaciclib · Ramucirumab · LY3023414
Carcinoma, Non-Small-Cell Lung →